nach oben

Drugs

Erschienen in:

01.06.2022 | Current Opinion

Prevention and Treatment of Monkeypox

verfasst von: John G. Rizk, Giuseppe Lippi, Brandon M. Henry, Donald N. Forthal, Youssef Rizk

Erschienen in: Drugs | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, and via fomites such as towels and bedding. Multiple medical countermeasures are stockpiled for orthopoxviruses such as monkeypox. Two vaccines are currently available, JYNNEOS^TM (live, replication incompetent vaccinia virus) and ACAM2000^® (live, replication competent vaccinia virus). While most cases of monkeypox will have mild and self-limited disease, with supportive care being typically sufficient, antivirals (e.g. tecovirimat, brincidofovir, cidofovir) and vaccinia immune globulin intravenous (VIGIV) are available as treatments. Antivirals can be considered in severe disease, immunocompromised patients, pediatrics, pregnant and breastfeeding women, complicated lesions, and when lesions appear near the mouth, eyes, and genitals. The purpose of this short review is to describe each of these countermeasures.

Monkeypox in Multiple Countries. https://wwwnc.cdc.gov/travel/notices/alert/monkeypox. Accessed 25 May 2022.

Yang Z. Monkeypox: A potential global threat? [published online ahead of print, 2022 May 25]. J Med Virol. 2022. https://doi.org/10.1002/jmv.27884.CrossRefPubMedPubMedCentral

Realegeno S, Puschnik AS, Kumar A, et al. Monkeypox virus host factor screen using haploid cells identifies essential role of GARP complex in extracellular virus formation. J Virol. 2017. https://doi.org/10.1128/jvi.00011-17.CrossRefPubMedPubMedCentral

Guarner J, Del Rio C, Malani PN. Monkeypox in 2022—what clinicians need to know [published online ahead of print, 2022 Jun 13]. JAMA. 2022. https://doi.org/10.1001/jama.2022.10802.CrossRefPubMed

Durski KN, McCollum AM, Nakazawa Y, et al. Emergence of monkeypox in West Africa and Central Africa, 1970–2017. Wkly Epidemiol Rec. 2018;93(11):125–132. Published 2018 Mar 16.

Monkeypox virus infection in the united states and other non-endemic countries—2022. https://emergency.cdc.gov/han/2022/han00466.asp. Accessed 25 May 2022.

CDC and health partners responding to Monkeypox Case in the US. https://www.cdc.gov/media/releases/2022/s0518-monkeypox-case.html. Accessed 25 May 2022.

Monkeypox—signs and symptoms. https://www.cdc.gov/poxvirus/monkeypox/symptoms.html. Accessed 25 May 2022.

Centers for Disease Control and Prevention. What clinicians need to know about Monkeypox in the United States and other countries. Accessed 15 June 2022.

10.

Monkeypox—treatment. https://www.cdc.gov/poxvirus/monkeypox/clinicians/treatment.html. Accessed 25 May 2022.

11.

Monkeypox: background information. Accessed 15 June 2022.

12.

Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull. 1998. https://doi.org/10.1093/oxfordjournals.bmb.a011720.CrossRefPubMed

13.

Hammarlund E, Lewis MW, Carter SV, et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med. 2005. https://doi.org/10.1038/nm1273.CrossRefPubMed

14.

US Centers for Disease Control and Prevention (CDC). Smallpox vaccines. Updated December 2, 2019. https://www.cdc.gov/smallpox/clinicians/vaccines.html. Accessed 25 May 2022.

15.

FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox. https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox. Accessed 25 May 2022.

16.

JYNNEOS [Package Insert]. Kvistgård, Denmark: Bavarian Nordic A/S: 2019. https://www.fda.gov/media/131078/download. Accessed 25 May 2022.

17.

Fine PEM, Jezek Z, Grab B, Dixon H. The transmission potential of monkeypox virus in human populations. Int J Epidemiol. 1988. https://doi.org/10.1093/ije/17.3.643.CrossRefPubMed

18.

Kupferschmidt K. As monkeypox threat grows, scientists debate best vaccine strategy.

19.

ACAM2000 [Package Insert]. Gaithersburg, MD: Emergent Product Development Gaithersburg Inc 2007. https://www.fda.gov/media/75792/download. Accessed May 2022.

20.

Vaccines—Smallpox. https://www.cdc.gov/smallpox/clinicians/vaccines.html. Accessed 25 May 2022.

21.

Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations, part II. Infect Dis Ther. 2017. https://doi.org/10.1007/s40121-017-0165-y.CrossRefPubMedPubMedCentral

22.

2022 United States Monkeypox Case. https://www.cdc.gov/poxvirus/monkeypox/outbreak/current.html. Accessed 25 May 2022.

23.

Petersen BW, Harms TJ, Reynolds MG, Harrison LH. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses—recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep. 2016. https://doi.org/10.15585/mmwr.mm6510a2.CrossRefPubMed

24.

Monitoring People Who Have Been Exposed. https://www.cdc.gov/poxvirus/monkeypox/clinicians/monitoring.html. Accessed 25 May 2022.

25.

US Centers for Disease Control and Prevention (CDC). Monkeypox and smallpox vaccine guidance. Updated December 2, 2019. https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html. Accessed 25 May 2022.

26.

Reynolds MG, McCollum AM, Nguete B, Lushima RS, Petersen BW. Improving the care and treatment of monkeypox patients in low-resource settings: applying evidence from contemporary biomedical and smallpox biodefense research. Viruses. 2017. https://doi.org/10.3390/v9120380.CrossRefPubMedPubMedCentral

27.

Adler H, Gould S, Hine P, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022;S1473–3099(22)00228-6. https://doi.org/10.1016/S1473-3099(22)00228-6.

28.

TPOXX (tecovirimat) [Package Insert]. Corvallis, OR: SIGA Technologies, Inc. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208627s000lbl.pdf. Accessed 25 May 2022.

29.

Russo AT, Grosenbach DW, Chinsangaram J, et al. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther. 2021. https://doi.org/10.1080/14787210.2020.1819791.CrossRefPubMed

30.

Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018. https://doi.org/10.1056/nejmoa1705688.CrossRefPubMedPubMedCentral

31.

Quenelle DC, Buller RML, Parker S, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007. https://doi.org/10.1128/AAC.00879-06.CrossRefPubMedPubMedCentral

32.

Marcinak J, Vora S, Weber S, et al. Household transmission of vaccinia virus from contact with a military smallpox vaccine—Illinois and Indiana, 2007. Morb Mortal Wkly Rep. 2007.

33.

Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis. 2008. https://doi.org/10.1086/587668.CrossRefPubMed

34.

Hahne S, Macey J, Binnendijk RV, et al. Progressive vaccinia in a military smallpox vaccine—United States, 2009. Pediatr Infect Dis J. 2009. https://doi.org/10.1097/inf.0b013e3181b18ed0

35.

US Food and Drug Administration: FDA approves drug to treat smallpox. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-treat-smallpox. Accessed 25 May 2022.

36.

Chittick G, Morrison M, Brundage T, Nichols WG. Short-term clinical safety profile of brincidofovir: a favorable benefit–risk proposition in the treatment of smallpox. Antiviral Res. 2017. https://doi.org/10.1016/j.antiviral.2017.01.009.CrossRefPubMed

37.

Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections. Viruses. 2010. https://doi.org/10.3390/v2122740.CrossRefPubMedPubMedCentral

38.

Rice AD, Adams MM, Wallace G, et al. Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011. https://doi.org/10.3390/v3010047.CrossRefPubMedPubMedCentral

39.

Parker S, Chen NG, Foster S, et al. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox—an animal model of smallpox. Antiviral Res. 2012. https://doi.org/10.1016/j.antiviral.2012.02.005.CrossRefPubMedPubMedCentral

40.

Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008. https://doi.org/10.1177/095632020801900302.CrossRefPubMed

41.

Baker RO, Bray M, Huggins JW. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003. https://doi.org/10.1016/S0166-3542(02)00196-1.CrossRefPubMed

42.

Wittek R. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int J Infect Dis. 2006. https://doi.org/10.1016/j.ijid.2005.12.001.CrossRefPubMed

43.

Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis. 2005. https://doi.org/10.1086/498155.CrossRefPubMed

Titel: Prevention and Treatment of Monkeypox
verfasst von: John G. Rizk
Giuseppe Lippi
Brandon M. Henry
Donald N. Forthal
Youssef Rizk
Publikationsdatum: 01.06.2022
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 9/2022
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-022-01742-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Tixagevimab + Cilgavimab: First Approval

Carotegrast Methyl: First Approval

Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review

In Search of the Optimal Antithrombotic Regimen for Intracerebral Hemorrhage Survivors with Atrial Fibrillation

Correction to: Nirmatrelvir Plus Ritonavir: First Approval

Oteseconazole: First Approval